PURPOSE: The appearance of a secondary @entity231 constitutes the most common complication of @entity231 surgery since the advent of phacoemulsification. Prevention is today one of the crucial challenges of research in ophthalmology. We have developed a drug-sustained capsular ring releasing @entity1487 ( @entity1487 ). This system targets the goal of combining advantageous mechanical and pharmacological properties with the ability to interfere on the epithelial cellular processes of secondary @entity231 . This paper presents the results of animal evaluation. MATERIAL AND METHODS: The study first developed the in vitro delivery system as a preliminary step to the animal in vivo approach. After a pilot study conducted on micro @entity1707 , lens extraction was performed on the right eye of 22 female albino @entity95 . The four study groups included: group 1 (6 animals) as a control group receiving only phacoemulsification; group 2 (6 animals) receiving phacoemulsification and the implantation of a nonsustained capsular tension ring; and group 3 (6 animals) receiving a drug-sustained ring. Group 4 (4 animals), implanted with a @entity1487 -sustained ring, was reserved for staged samples of @entity7462 for kinetic determination of active agent release. RESULTS: Clinical evaluation based on biomicroscopy and histology showed a lesser reaction of secondary @entity231 in eyes with the ring. Compared to group 1, central posterior capsular @entity3236 appeared significantly lower in density and surface in groups 2 and 3. No intraocular @entity137 was observed. The poor sensitivity of the @entity1487 detection method (high-performance chromatography) impaired pharmacokinetic evaluation. DISCUSSION:                 <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The decrease in secondary @entity231 reaction in cases of implanted capsular ring demonstrated the advantages of its mechanical effect. However, the benefit of an additive pharmacological action related to the release of @entity1487 could not be proved. Nevertheless, the theoretical concept of a drug-sustained delivery system seems attractive and thus calls for evaluation of other potential modulators of cell behavior.

[Nonbiodegradable drug-sustained capsular ring for prevention of secondary XXXX . Part II: In vivo evaluation].

@entity1707 :: ('9823', 'Species') :: ['pigs'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract'] @entity95 :: ('9986', 'Species') :: ['rabbits'] @entity7462 :: ('MESH:C562390', 'Disease') :: ['aqueous humor'] @entity3236 :: ('MESH:D058442', 'Disease') :: ['opacification'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU', '5-fluorouracil']
@entity231 :: (MESH:D002386,Disease) :: ['cataract']
